Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation

Trial Profile

Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2012 Planned end date changed from 1 Aug 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top